TCTMD News http://www.tctmd.com/news/rss TCTMD News en Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides http://www.tctmd.com/news/therapies-aimed-new-genetic-target-show-early-promise-lowering-triglycerides <span class="field field--name-title field--type-string field--label-hidden">Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/therapies-aimed-new-genetic-target-show-early-promise-lowering-triglycerides"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.26.17.water_.header.jpg?itok=aXMwD3oX" width="220" height="128" alt="Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/26/2017 - 14:52</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Mouse studies and phase I human trials suggest that inhibiting ANGPTL3 may yield dividends down the road.</div> Fri, 26 May 2017 18:52:38 +0000 yplata 22618 at http://www.tctmd.com Featured Fellow: Ankur Kalra, MD http://www.tctmd.com/news/featured-fellow-ankur-kalra-md <span class="field field--name-title field--type-string field--label-hidden">Featured Fellow: Ankur Kalra, MD</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/26/2017 - 12:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Already reading papers on coronary stents in high school, this second-year interventional fellow now values humility and perseverance in his peers and mentors.</div> Fri, 26 May 2017 16:51:10 +0000 yplata 22617 at http://www.tctmd.com DAWN Trial May Lay Groundwork for Extending Treatment Window for Acute Stroke Therapy http://www.tctmd.com/news/dawn-trial-may-lay-groundwork-extending-treatment-window-acute-stroke-therapy <span class="field field--name-title field--type-string field--label-hidden">DAWN Trial May Lay Groundwork for Extending Treatment Window for Acute Stroke Therapy</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/dawn-trial-may-lay-groundwork-extending-treatment-window-acute-stroke-therapy"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.26.17.dawn_.jpg?itok=dSBMb186" width="220" height="119" alt="DAWN Trial May Lay Groundwork for Extending Treatment Window for Acute Stroke Therapy" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/26/2017 - 10:35</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Looking at age, severity of stroke symptoms, and infarct size may help identify patients who can benefit up to 24 hours after onset.</div> Fri, 26 May 2017 14:35:12 +0000 yplata 22614 at http://www.tctmd.com Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis http://www.tctmd.com/news/embolic-protection-during-tavr-reduces-volume-cerebral-lesions-clinical-benefit-not-evident <span class="field field--name-title field--type-string field--label-hidden">Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/embolic-protection-during-tavr-reduces-volume-cerebral-lesions-clinical-benefit-not-evident"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.26.17.known_.jpg?itok=r46c2Zmo" width="220" height="127" alt="Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/26/2017 - 10:12</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The clinical significance of lesion volume is unknown, so lower-risk TAVR patients should be followed long-term, say investigators. </div> Fri, 26 May 2017 14:12:10 +0000 yplata 22613 at http://www.tctmd.com Closer Follow-up of Preeclampsia in Pregnancy Needed to Reduce Risk of Stroke http://www.tctmd.com/news/closer-follow-preeclampsia-pregnancy-needed-reduce-risk-stroke <span class="field field--name-title field--type-string field--label-hidden">Closer Follow-up of Preeclampsia in Pregnancy Needed to Reduce Risk of Stroke</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/closer-follow-preeclampsia-pregnancy-needed-reduce-risk-stroke"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.25.17.pregnancy.jpg?itok=ofXbCgpn" width="220" height="131" alt="Closer Follow-up of Preeclampsia in Pregnancy Needed to Reduce Risk of Stroke" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/25/2017 - 15:21</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Paying attention to modifiable risk factors and screening for bleeding disorders and blood clots may aid prevention efforts, researchers say.</div> Thu, 25 May 2017 19:21:05 +0000 yplata 22609 at http://www.tctmd.com Cardiovascular Disease Is a Major Worldwide Threat to Public Health, Global Analysis Finds http://www.tctmd.com/news/cardiovascular-disease-major-worldwide-threat-public-health-global-analysis-finds <span class="field field--name-title field--type-string field--label-hidden">Cardiovascular Disease Is a Major Worldwide Threat to Public Health, Global Analysis Finds</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/cardiovascular-disease-major-worldwide-threat-public-health-global-analysis-finds"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.25.17.world_.header.jpg?itok=9GC5rQ1w" width="220" height="128" alt="Cardiovascular Disease Is a Major Worldwide Threat to Public Health, Global Analysis Finds" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/25/2017 - 12:17</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/alison-palkhivala" hreflang="en">Alison Palkhivala</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">While CVD’s impact defies regional and socioeconomic barriers, middle-income countries currently face the highest burden.</div> Thu, 25 May 2017 16:17:22 +0000 yplata 22608 at http://www.tctmd.com EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure http://www.tctmd.com/news/ewolution-analysis-backs-laa-closure-high-risk-patients-taking-dapt-not-warfarin-after <span class="field field--name-title field--type-string field--label-hidden">EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/ewolution-analysis-backs-laa-closure-high-risk-patients-taking-dapt-not-warfarin-after"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/brain.header.jpg?itok=V86jREVs" width="220" height="116" alt="EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/24/2017 - 13:14</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">This substudy suggests LAA closure is safe and reduces the risk of ischemic stroke in patients who are only taking DAPT. </div> Wed, 24 May 2017 17:14:50 +0000 yplata 22605 at http://www.tctmd.com Episdoe 21: ILUMIEN III - OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in CAD http://www.tctmd.com/audio/episdoe-21-ilumien-iii-oct-guided-vs-ivus-guided-vs-angio-guided-stent-implantation-cad <span class="field field--name-title field--type-string field--label-hidden">Episdoe 21: ILUMIEN III - OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in CAD</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/24/2017 - 12:21</span> <div class="field field--name-field-date field--type-datetime field--label-above"> <!-- <div class="field__label">Publish Date</div> --> <div class="field__item">2 days 5 hours ago</div> </div> <div class="field field--name-field-teaser field--type-string-long field--label-above"> <!-- <div class="field__label">Teaser</div> --> <div class="field__item">C. Michael Gibson discusses the late-breaking trial results with Ziad Ali.</div> </div> Wed, 24 May 2017 16:21:10 +0000 yplata 22603 at http://www.tctmd.com TCTMD Talking Points HeartMate II Left Ventricular Assist System Under Recall Due to Controller Exchange Problems http://www.tctmd.com/news/heartmate-ii-left-ventricular-assist-system-under-recall-due-controller-exchange-problems <span class="field field--name-title field--type-string field--label-hidden">HeartMate II Left Ventricular Assist System Under Recall Due to Controller Exchange Problems</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/24/2017 - 11:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">There have been 70 reports of incidents related to the exchange issue, including 19 injuries and 26 deaths.</div> Wed, 24 May 2017 15:51:36 +0000 yplata 22601 at http://www.tctmd.com Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke http://www.tctmd.com/news/two-new-trials-buoy-outlook-pfo-closure-patients-cryptogenic-stroke <span class="field field--name-title field--type-string field--label-hidden">Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/two-new-trials-buoy-outlook-pfo-closure-patients-cryptogenic-stroke"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/glove.header.jpg?itok=aGNCNnZC" width="220" height="127" alt="Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/24/2017 - 11:28</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">REDUCE and CLOSE both met their primary endpoints, but one expert advised waiting for more details before considering guideline changes.</div> Wed, 24 May 2017 15:28:39 +0000 yplata 22600 at http://www.tctmd.com Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI http://www.tctmd.com/news/triple-therapy-not-being-widely-used-fib-patients-undergoing-pci <span class="field field--name-title field--type-string field--label-hidden">Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/triple-therapy-not-being-widely-used-fib-patients-undergoing-pci"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/billard.header.jpg?itok=iXkbATNf" width="220" height="126" alt="Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/23/2017 - 16:03</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Long-term follow up from the ASAN-PCI registry shows triple therapy did not decrease ischemic events but did increase bleeding risk.</div> Tue, 23 May 2017 20:03:35 +0000 yplata 22598 at http://www.tctmd.com How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts http://www.tctmd.com/news/how-low-can-you-go-concerns-over-aggressive-ldl-lowering-eased-pcsk9-evidence-mounts <span class="field field--name-title field--type-string field--label-hidden">How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/how-low-can-you-go-concerns-over-aggressive-ldl-lowering-eased-pcsk9-evidence-mounts"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/650x330.cholesterol.feature.jpg?itok=_gmJokuh" width="220" height="112" alt="How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/23/2017 - 14:23</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Experts say FOURIER helped assuage concerns over cognitive effects, cataracts, and diabetes but that many more years of data are needed.</div> Tue, 23 May 2017 18:23:17 +0000 yplata 22596 at http://www.tctmd.com Anabolic Steroid Use Linked With Myocardial Dysfunction and Accelerated Atherosclerosis http://www.tctmd.com/news/anabolic-steroid-use-linked-myocardial-dysfunction-and-accelerated-atherosclerosis <span class="field field--name-title field--type-string field--label-hidden">Anabolic Steroid Use Linked With Myocardial Dysfunction and Accelerated Atherosclerosis</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/anabolic-steroid-use-linked-myocardial-dysfunction-and-accelerated-atherosclerosis"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/gym.header.jpg?itok=aONKdqDX" width="220" height="128" alt="Anabolic Steroid Use Linked With Myocardial Dysfunction and Accelerated Atherosclerosis" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/23/2017 - 10:58</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/alison-palkhivala" hreflang="en">Alison Palkhivala</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings are a public health concern, given that as many as 1% of young men, not all of them athletes, may use these agents.</div> Tue, 23 May 2017 14:58:27 +0000 yplata 22595 at http://www.tctmd.com DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting http://www.tctmd.com/news/disrupt-cad-lithoplasty-may-modify-dense-calcium-coronary-lesions-stenting <span class="field field--name-title field--type-string field--label-hidden">DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/disrupt-cad-lithoplasty-may-modify-dense-calcium-coronary-lesions-stenting"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/machine.header.jpg?itok=nqgsvsWH" width="220" height="131" alt="DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/22/2017 - 12:14</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The novel device might one day challenge standard balloon angioplasty for this select patient population, one expert says.</div> Mon, 22 May 2017 16:14:05 +0000 yplata 22592 at http://www.tctmd.com Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate http://www.tctmd.com/news/best-antiplatelet-therapy-real-world-pci-european-registries-fuel-debate <span class="field field--name-title field--type-string field--label-hidden">Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/best-antiplatelet-therapy-real-world-pci-european-registries-fuel-debate"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/earth.header.jpg?itok=F2uTsKLN" width="220" height="126" alt="Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/22/2017 - 10:34</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Figures from BCIS and SCAAR suggest that what happens in clinical practice may not reflect the world of randomized trials.</div> Mon, 22 May 2017 14:34:17 +0000 yplata 22585 at http://www.tctmd.com Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI http://www.tctmd.com/news/large-us-study-suggests-little-difference-between-bivalirudin-and-heparin-transradial-primary <span class="field field--name-title field--type-string field--label-hidden">Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/large-us-study-suggests-little-difference-between-bivalirudin-and-heparin-transradial-primary"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/device.header.jpg?itok=Sle7OzdK" width="220" height="111" alt="Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/22/2017 - 10:01</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings seem to confirm results from the HEAT PPCI trial, but only another trial will answer remaining questions.</div> Mon, 22 May 2017 14:01:31 +0000 yplata 22583 at http://www.tctmd.com Slimmest Stent to Date Looks Promising in Small Study http://www.tctmd.com/news/slimmest-stent-date-looks-promising-small-study <span class="field field--name-title field--type-string field--label-hidden">Slimmest Stent to Date Looks Promising in Small Study</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/slimmest-stent-date-looks-promising-small-study"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/stent.header.jpg?itok=fNOf37GB" width="220" height="115" alt="Slimmest Stent to Date Looks Promising in Small Study" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/19/2017 - 10:33</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The single-arm study found low rates of target vessel failure at 1 year, but with no comparator arm, some questions remain.</div> Fri, 19 May 2017 14:33:28 +0000 yplata 22581 at http://www.tctmd.com Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis http://www.tctmd.com/news/scaffold-thrombosis-unpredictable-absorb-aida-analysis <span class="field field--name-title field--type-string field--label-hidden">Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/scaffold-thrombosis-unpredictable-absorb-aida-analysis"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/question.header.jpg?itok=95BydavW" width="220" height="134" alt="Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/19/2017 - 09:17</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Unlike in the ABSORB studies, even adhering to good implantation techniques failed to limit the risk of device thrombosis.</div> Fri, 19 May 2017 13:17:17 +0000 yplata 22580 at http://www.tctmd.com Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It http://www.tctmd.com/news/access-denied-stem-cell-therapy-shows-some-promise-refractory-angina-patients-cant-get-it <span class="field field--name-title field--type-string field--label-hidden">Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/access-denied-stem-cell-therapy-shows-some-promise-refractory-angina-patients-cant-get-it"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/brokenheart.jpg?itok=403AnsRT" width="220" height="126" alt="Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/19/2017 - 07:59</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Although the CD34+ therapy trials have been halted, patient-level data hint at functional and mortality benefits.</div> Fri, 19 May 2017 11:59:13 +0000 yplata 22579 at http://www.tctmd.com More Early Stroke With SAVR Than TAVR in SURTAVI http://www.tctmd.com/news/more-early-stroke-savr-tavr-surtavi <span class="field field--name-title field--type-string field--label-hidden">More Early Stroke With SAVR Than TAVR in SURTAVI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/more-early-stroke-savr-tavr-surtavi"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/surtavi.header.jpg?itok=Z54Oi8t6" width="220" height="125" alt="More Early Stroke With SAVR Than TAVR in SURTAVI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/18/2017 - 10:02</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">A close review of neurological outcomes suggests that TAVR may have the edge early on, although differences disappear by 2 years.</div> Thu, 18 May 2017 14:02:56 +0000 yplata 22573 at http://www.tctmd.com Transradial PCI in ACS Reduces Risk of Acute Kidney Injury http://www.tctmd.com/news/transradial-pci-acs-reduces-risk-acute-kidney-injury <span class="field field--name-title field--type-string field--label-hidden">Transradial PCI in ACS Reduces Risk of Acute Kidney Injury</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/transradial-pci-acs-reduces-risk-acute-kidney-injury"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/way.header.jpg?itok=vjnRoG4b" width="220" height="138" alt="Transradial PCI in ACS Reduces Risk of Acute Kidney Injury" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/18/2017 - 10:10</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Despite previous concerns, the transradial approach was not associated with higher contrast use, at least in these experienced operators. </div> Thu, 18 May 2017 14:10:00 +0000 yplata 22574 at http://www.tctmd.com EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions http://www.tctmd.com/news/eurocto-revascularization-bests-medical-therapy-quality-life-cto-lesions <span class="field field--name-title field--type-string field--label-hidden">EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/eurocto-revascularization-bests-medical-therapy-quality-life-cto-lesions"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/EUROCTO.header.jpg?itok=FXeLz8zR" width="220" height="135" alt="EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/18/2017 - 07:36</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The data might not be enough to convince staunch CTO PCI opponents, but they should inform guidelines, the lead investigator says.</div> Thu, 18 May 2017 11:36:47 +0000 yplata 22572 at http://www.tctmd.com FFR-SEARCH Explores Potential of Physiologic Assessment After PCI http://www.tctmd.com/news/ffr-search-explores-potential-physiologic-assessment-after-pci <span class="field field--name-title field--type-string field--label-hidden">FFR-SEARCH Explores Potential of Physiologic Assessment After PCI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/ffr-search-explores-potential-physiologic-assessment-after-pci"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/audience.header.jpg?itok=GAo58zxy" width="220" height="116" alt="FFR-SEARCH Explores Potential of Physiologic Assessment After PCI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/18/2017 - 07:25</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Early data show nearly half of patients have at least one lesion with an FFR value below 0.90 even when stenting looks fine on angiography.</div> Thu, 18 May 2017 11:25:30 +0000 yplata 22571 at http://www.tctmd.com Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year http://www.tctmd.com/news/minority-women-face-50-increased-risk-deathmi-after-pci-compared-white-men-1-year <span class="field field--name-title field--type-string field--label-hidden">Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/minority-women-face-50-increased-risk-deathmi-after-pci-compared-white-men-1-year"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/hands.header.jpg?itok=l4kSA-w4" width="220" height="139" alt="Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/18/2017 - 07:03</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">A subanalysis from the PLATINUM DIVERSITY study suggests a need to “peel the onion” on important differences in risk.</div> Thu, 18 May 2017 11:03:25 +0000 yplata 22569 at http://www.tctmd.com BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI http://www.tctmd.com/news/bio-resort-impaired-glucose-metabolism-linked-worse-clinical-outcomes-after-pci <span class="field field--name-title field--type-string field--label-hidden">BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/bio-resort-impaired-glucose-metabolism-linked-worse-clinical-outcomes-after-pci"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/blood.header.jpg?itok=lLmIbM1T" width="220" height="120" alt="BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 12:27</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Despite modern DES, those with diabetes and prediabetes fared a lot worse after PCI than those with normal glucose metabolism. </div> Wed, 17 May 2017 16:27:45 +0000 yplata 22565 at http://www.tctmd.com Episode 13: Left Main Revascularization, Bifurcation Stenting, and LAA Closure http://www.tctmd.com/audio/episode-13-left-main-revascularization-bifurcation-stenting-and-laa-closure <span class="field field--name-title field--type-string field--label-hidden">Episode 13: Left Main Revascularization, Bifurcation Stenting, and LAA Closure </span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 12:00</span> <div class="field field--name-field-date field--type-datetime field--label-above"> <!-- <div class="field__label">Publish Date</div> --> <div class="field__item">1 week 2 days ago</div> </div> <div class="field field--name-field-teaser field--type-string-long field--label-above"> <!-- <div class="field__label">Teaser</div> --> <div class="field__item">This week&#039;s episode is hosted by Cindy Grines and features guests Antonio Colombo, Philippe Généreux, Vivek Reddy, and Gregg Stone.</div> </div> Wed, 17 May 2017 16:00:13 +0000 yplata 22563 at http://www.tctmd.com TCT Radio TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years http://www.tctmd.com/news/tavr-durability-some-reassurances-corevalve-trials-out-9-years <span class="field field--name-title field--type-string field--label-hidden">TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/tavr-durability-some-reassurances-corevalve-trials-out-9-years"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/reloj.header.jpg?itok=KgaHRGI7" width="220" height="123" alt="TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 10:41</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">New data presented at EuroPCR add clarity to ongoing conversations on durability and deterioration with the self-expanding valve.</div> Wed, 17 May 2017 14:41:56 +0000 yplata 22561 at http://www.tctmd.com Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters http://www.tctmd.com/news/bicuspid-patients-calcification-fare-worse-after-tavr-device-type-matters <span class="field field--name-title field--type-string field--label-hidden">Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/bicuspid-patients-calcification-fare-worse-after-tavr-device-type-matters"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/Yoon-bicuspid.jpg?itok=2srjnFsm" width="220" height="122" alt="Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 10:34</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Although event rates differed by bicuspid AS morphology, next-generation TAVR devices seemed to eliminate the risks.</div> Wed, 17 May 2017 14:34:21 +0000 yplata 22560 at http://www.tctmd.com If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year http://www.tctmd.com/news/if-they-survive-first-month-mitral-annular-calcification-patients-treated-transcatheter-valves <span class="field field--name-title field--type-string field--label-hidden">If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/if-they-survive-first-month-mitral-annular-calcification-patients-treated-transcatheter-valves"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/MAC-globalreg.header.jpg?itok=IbExTXK6" width="220" height="121" alt="If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 10:00</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The MAC Global Registry has faced some setbacks, but trial and error has paid off in these patients who otherwise have limited options.</div> Wed, 17 May 2017 14:00:56 +0000 yplata 22557 at http://www.tctmd.com The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone http://www.tctmd.com/news/arte-antiplatelet-therapy-after-tavr-bleeding-greater-clopidogrel-plus-aspirin-vs-aspirin <span class="field field--name-title field--type-string field--label-hidden">The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/arte-antiplatelet-therapy-after-tavr-bleeding-greater-clopidogrel-plus-aspirin-vs-aspirin"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/arte.header.jpg?itok=Zh5EEGCp" width="220" height="130" alt="The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 08:05</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The study author said he no longer uses clopidogrel as a result of these findings, but others argue the results need replication.</div> Wed, 17 May 2017 12:05:34 +0000 yplata 22556 at http://www.tctmd.com ‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry http://www.tctmd.com/news/reassuring-results-watchman-laa-closure-device-seen-ewolution-registry <span class="field field--name-title field--type-string field--label-hidden">‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/reassuring-results-watchman-laa-closure-device-seen-ewolution-registry"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/light.header.jpg?itok=8NGDibBJ" width="220" height="119" alt="‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 07:05</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">New 1-year data show low rates of stroke and bleeding among high-risk patients, most of whom have contraindications to warfarin. </div> Wed, 17 May 2017 11:05:56 +0000 yplata 22555 at http://www.tctmd.com No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan http://www.tctmd.com/news/no-very-late-scaffold-thrombosis-risk-absorb-bvs-studies-china-japan <span class="field field--name-title field--type-string field--label-hidden">No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/no-very-late-scaffold-thrombosis-risk-absorb-bvs-studies-china-japan"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/image3.tier1__0.jpg?itok=v7GXvGwS" width="220" height="146" alt="No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13826" typeof="schema:Person" property="schema:name" datatype="">sgutch</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 05/17/2017 - 04:33</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Patient selection, vessel size, and implantation technique continue to dominate discussions on how this device performs.</div> Wed, 17 May 2017 08:33:36 +0000 sgutch 22554 at http://www.tctmd.com Abbott Vascular Recalls Three Coronary Catheters Because of Possible Sheath Removal Problems http://www.tctmd.com/news/abbott-vascular-recalls-three-coronary-catheters-because-possible-sheath-removal-problems <span class="field field--name-title field--type-string field--label-hidden">Abbott Vascular Recalls Three Coronary Catheters Because of Possible Sheath Removal Problems</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/16/2017 - 11:08</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The US FDA has designated the action as Class I. One patient is known to have died from complications secondary to a failed balloon deflation.</div> Tue, 16 May 2017 15:08:20 +0000 yplata 22551 at http://www.tctmd.com REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial http://www.tctmd.com/news/reprise-iii-lotus-valve-matches-corevalve-first-large-head-head-tavr-trial <span class="field field--name-title field--type-string field--label-hidden">REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/reprise-iii-lotus-valve-matches-corevalve-first-large-head-head-tavr-trial"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/presentation.header.png?itok=puNjdT-e" width="220" height="129" alt="REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/16/2017 - 10:07</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Lotus carried low rates of death, stroke, and paravalvular leak, but pacemaker implantations were higher than with CoreValve.</div> Tue, 16 May 2017 14:07:26 +0000 yplata 22550 at http://www.tctmd.com iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows http://www.tctmd.com/news/ifr-and-ffr-equally-safe-deferring-revascularization-pooled-analysis-shows <span class="field field--name-title field--type-string field--label-hidden">iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/ifr-and-ffr-equally-safe-deferring-revascularization-pooled-analysis-shows"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/sign.header.jpg?itok=dTRwgst0" width="220" height="128" alt="iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/16/2017 - 09:26</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Combined data from DEFINE-FLAIR and iFR-SWEDEHEART suggest that clinical presentation may influence functional assessment results.</div> Tue, 16 May 2017 13:26:44 +0000 yplata 22546 at http://www.tctmd.com DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit http://www.tctmd.com/news/dessolve-iii-mistent-holds-well-against-xience-12-months-hints-potential-longer-term-benefit <span class="field field--name-title field--type-string field--label-hidden">DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/dessolve-iii-mistent-holds-well-against-xience-12-months-hints-potential-longer-term-benefit"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/MiSTENT.header.jpg?itok=olg5o6iy" width="220" height="122" alt="DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/16/2017 - 08:52</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The MiStent bioresorbable polymer dissolves within 3 months but sirolimus microcrystals embedded in the wall stick around much longer.</div> Tue, 16 May 2017 12:52:05 +0000 yplata 22544 at http://www.tctmd.com TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS http://www.tctmd.com/news/topic-replacing-p2y12-inhibitors-clopidogrel-1-month-after-pci-saves-money-prevents-bleeding <span class="field field--name-title field--type-string field--label-hidden">TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/topic-replacing-p2y12-inhibitors-clopidogrel-1-month-after-pci-saves-money-prevents-bleeding"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/europcr.triomphe.header.jpg?itok=ed4kLFPO" width="220" height="117" alt="TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 05/16/2017 - 07:21</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">(UPDATED) The single-center study has economic and clinical implications for a strategy already in use in some parts of the world.</div> Tue, 16 May 2017 11:21:42 +0000 yplata 22543 at http://www.tctmd.com Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk http://www.tctmd.com/news/registry-study-supports-curbing-cholesterol-screening-young-adults-because-low-overall-risk <span class="field field--name-title field--type-string field--label-hidden">Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/registry-study-supports-curbing-cholesterol-screening-young-adults-because-low-overall-risk"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/arm.header.2.jpg?itok=cmrUj0Ad" width="220" height="136" alt="Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/15/2017 - 13:16</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">While the authors support limited use of cholesterol testing in young adults, experts say a more liberal approach is warranted until proven otherwise.</div> Mon, 15 May 2017 17:16:04 +0000 yplata 22539 at http://www.tctmd.com Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk http://www.tctmd.com/news/lipid-rich-plaque-nonculprit-regions-target-vessel-predicts-future-mace-risk <span class="field field--name-title field--type-string field--label-hidden">Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/lipid-rich-plaque-nonculprit-regions-target-vessel-predicts-future-mace-risk"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/artery.header.updated.jpg?itok=h3Hot6ZD" width="220" height="144" alt="Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/15/2017 - 12:55</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings argue for secondary prevention to treat the overall patient rather than make the case for intervening on nonculprit plaques.</div> Mon, 15 May 2017 16:55:52 +0000 yplata 22538 at http://www.tctmd.com Tool May Help Select Patients for Endovascular Stroke Treatment http://www.tctmd.com/news/tool-may-help-select-patients-endovascular-stroke-treatment <span class="field field--name-title field--type-string field--label-hidden">Tool May Help Select Patients for Endovascular Stroke Treatment</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/15/2017 - 12:29</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The data provide insight into prognostic factors, but one expert predicts the tool won’t be used widely in clinical practice.</div> Mon, 15 May 2017 16:29:31 +0000 yplata 22536 at http://www.tctmd.com Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate http://www.tctmd.com/news/big-questions-bioresorbable-scaffolds-experts-and-innovators-debate <span class="field field--name-title field--type-string field--label-hidden">Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/big-questions-bioresorbable-scaffolds-experts-and-innovators-debate"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/euro.meeting.header.jpg?itok=yMAL1mxb" width="220" height="124" alt="Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/15/2017 - 10:21</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Strut size, implantation techniques, and PCSK9 inhibitors: everything was on the table during an innovation session that kicked off EuroPCR.</div> Mon, 15 May 2017 14:21:52 +0000 yplata 22535 at http://www.tctmd.com Bioresorbable Scaffolds: Where Do We Go From Here? http://www.tctmd.com/news/bioresorbable-scaffolds-where-do-we-go-here <span class="field field--name-title field--type-string field--label-hidden">Bioresorbable Scaffolds: Where Do We Go From Here? </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/bioresorbable-scaffolds-where-do-we-go-here"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/microphone.header.jpg?itok=EoTo65sk" width="220" height="132" alt="Bioresorbable Scaffolds: Where Do We Go From Here? " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/15/2017 - 06:56</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Two prominent physicians tasked with debating the future of BRS at SCAI ultimately seemed to agree that caution now may pay off long term.</div> Mon, 15 May 2017 10:56:16 +0000 yplata 22534 at http://www.tctmd.com EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40 http://www.tctmd.com/news/europcr-2017-new-stents-new-questions-pci-today-and-tomorrow-angioplasty-turns-40 <span class="field field--name-title field--type-string field--label-hidden">EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/europcr-2017-new-stents-new-questions-pci-today-and-tomorrow-angioplasty-turns-40"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/coffe.header.jpg?itok=-w-1PMJ9" width="220" height="127" alt="EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/12/2017 - 17:49</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">There’s plenty of valve and other programming to keep structural folks content, but this year’s sessions put a heavy focus on coronary disease. </div> Fri, 12 May 2017 21:49:10 +0000 yplata 22533 at http://www.tctmd.com Domo Arigato: High Success Rates, Low Radiation With Both Radial and Femoral Robotic PCI http://www.tctmd.com/news/domo-arigato-high-success-rates-low-radiation-both-radial-and-femoral-robotic-pci <span class="field field--name-title field--type-string field--label-hidden">Domo Arigato: High Success Rates, Low Radiation With Both Radial and Femoral Robotic PCI </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/domo-arigato-high-success-rates-low-radiation-both-radial-and-femoral-robotic-pci"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/panel.header_0.jpg?itok=X_1c86Wl" width="220" height="143" alt="Domo Arigato: High Success Rates, Low Radiation with Both Radial and Femoral Robotic PCI " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/12/2017 - 15:02</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Final results from the PRECISION registry hint that as adoption of this technology increases, truly “remote” procedures may become a reality.</div> Fri, 12 May 2017 19:02:57 +0000 yplata 22530 at http://www.tctmd.com $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor http://www.tctmd.com/news/2-billion-annual-price-tag-fourier-eligible-va-patients-pcsk9-inhibitor <span class="field field--name-title field--type-string field--label-hidden">$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/2-billion-annual-price-tag-fourier-eligible-va-patients-pcsk9-inhibitor"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/coin.header.jpg?itok=RCTPbYGX" width="220" height="129" alt="$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/12/2017 - 11:00</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/node/5" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">With a high-intensity statin and ezetimibe instead, more than 60% of patients wouldn’t need evolocumab, resulting in a big cost savings. </div> Fri, 12 May 2017 15:00:35 +0000 yplata 22529 at http://www.tctmd.com Fellow Talk: Early Career Tips from a Master Interventionalist http://www.tctmd.com/news/fellow-talk-early-career-tips-master-interventionalist <span class="field field--name-title field--type-string field--label-hidden">Fellow Talk: Early Career Tips from a Master Interventionalist</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/11/2017 - 17:35</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/ankur-kalra-md" hreflang="en">Ankur Kalra, MD </a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Structural fellow Ankur Kalra, MD, talks with David Holmes Jr, MD, over lunch about his best advice for starting a career after training ends.</div> Thu, 11 May 2017 21:35:42 +0000 yplata 22525 at http://www.tctmd.com New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke http://www.tctmd.com/news/new-onset-fib-after-tavr-linked-increased-risk-early-stroke <span class="field field--name-title field--type-string field--label-hidden">New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/new-onset-fib-after-tavr-linked-increased-risk-early-stroke"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/pad.header.jpg?itok=psKVwRe3" width="220" height="147" alt="New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 05/12/2017 - 10:00</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Post hoc analysis from the BRAVO-3 study found that despite their higher risk, not all A-fib patients were on anticoagulants at discharge.</div> Fri, 12 May 2017 14:00:44 +0000 yplata 22528 at http://www.tctmd.com Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women http://www.tctmd.com/news/rivaroxaban-appears-protect-against-mi-older-men-fib-not-women <span class="field field--name-title field--type-string field--label-hidden">Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/rivaroxaban-appears-protect-against-mi-older-men-fib-not-women"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/pills.2a.header.jpg?itok=KHZbfar8" width="220" height="120" alt="Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/11/2017 - 17:05</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The sex difference may be related to smaller size, lower creatinine clearance, or use of hormone replacement therapy in women, one expert says.</div> Thu, 11 May 2017 21:05:37 +0000 yplata 22524 at http://www.tctmd.com Nearly Half of Interventional Cardiologists May Have Pre-Cataract Lesions http://www.tctmd.com/news/nearly-half-interventional-cardiologists-may-have-pre-cataract-lesions <span class="field field--name-title field--type-string field--label-hidden">Nearly Half of Interventional Cardiologists May Have Pre-Cataract Lesions</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/nearly-half-interventional-cardiologists-may-have-pre-cataract-lesions"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/Cataract-header%20image.updated.jpg?itok=FxJmFxYq" width="220" height="126" alt="Nearly Half of Interventional Cardiologists May Have Pre-Cataract Lesions" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/11/2017 - 14:45</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Based on eye exams conducted at last year’s SCAI meeting, investigators say 47% of operators screened had radiation-related damage.</div> Thu, 11 May 2017 18:45:59 +0000 yplata 22523 at http://www.tctmd.com Avoiding Gluten May Backfire in Terms of Coronary Risk in the General Population, Study Suggests http://www.tctmd.com/news/avoiding-gluten-may-backfire-terms-coronary-risk-general-population-study-suggests <span class="field field--name-title field--type-string field--label-hidden">Avoiding Gluten May Backfire in Terms of Coronary Risk in the General Population, Study Suggests</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/avoiding-gluten-may-backfire-terms-coronary-risk-general-population-study-suggests"><img src="/sites/default/files/efs/public/styles/medium/public/2017-05/5.11.17.gluten.header.jpg?itok=EC_3lFAc" width="220" height="130" alt="Avoiding Gluten May Backfire in Terms of Coronary Risk in the General Population, Study Suggests" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 05/11/2017 - 09:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">People shunning gluten without medical grounds may be degrading the quality of their overall diet, one expert says.</div> Thu, 11 May 2017 13:51:47 +0000 yplata 22522 at http://www.tctmd.com